ACRP  >> Vol. 1 No. 1 (February 2013)

    Advantage of Prevention and Treatment in Neonatal Respiratory Distress Syndrome

  • 全文下载: PDF(287KB) HTML   XML   PP.10-15   DOI: 10.12677/ACRP.2013.11003  
  • 下载量: 1,842  浏览量: 11,476  



预防治疗呼吸窘迫综合征新生儿Prevention; Treatment; Respiratory Distress Syndrome; Newborn

一般认为,新生儿呼吸窘迫综合征(Neonatal respiratory distress syndrome, NRDS)是由于肺表面活性物质缺乏所致,近年研究认为NRDS的发病与胎龄、出生体重、窒息、剖宫产、感染、产前应用肾上腺皮质激素、糖尿病母亲、宫内慢性缺氧等多种因素有关。为了预防NRDS的发生,产前可给产妇应用糖皮质激素、氨溴索等药物,出生后可尽早给予大剂量氨溴索、肺表面活性物质(Pulmonary surfactant, PS)、持续呼吸道正压通气(Continuous positive air-way pressure, CPAP)、高频震荡通气(High-frequency oscillatory ventilation, HFOV)、吸入一氧化氮、液态通气及体外膜肺治疗以阻止病情的进展。

Neonatal respiratory distress syndrome (NRDS) is caused by deficiency of pulmonary surfactant (PS) in premature infants generally. But it is associated with gestational age, birthweight, asphyxia, caesarean birth, infection, use dexamethasone to mother before delivery, diabetic mother and fetus intrauterine hypoxia. Treated with ambroxol and dexamethasone to maternity before delivery may prevent the NRDS. High dose ambroxol, PS, continuous positive air-way pressure, high-frequency oscillatory ventilation, inhaled NO, liquid ventilation and extracorporeal membrane oxygenation may be used earlier to newborns after birth to avoid aggravation of the disease.

张立明, 王娜. 新生儿呼吸窘迫综合征的防治进展[J]. 亚洲儿科病例研究, 2013, 1(1): 10-15.


[1] X.-L. Ma, X.-F. Xu, C. Chen, et al. Epidemiology of respiratory distress and the illness severity in late preterm or term infants: A prospective multi-center study. Chinese Medical Journal, 2010, 123(20): 2776-2780.
[2] F. S. Cole, A. Hamvas and L. M. Nogee. Genetic disorders of neonatal respiratory function. Pediatric Research, 2001, 50(2): 157- 162.
[3] H.-Y. Yi, S. Xu and S.-J. Yang. Related factor analysis on term infant with respiratory distress syndrome. Chinese Journal of Neonatology, 2011, 26(5): 319-320.
[4] L. Jain, D. C. Eaton. Physiology of fetal lung fluid clearance and the effect to labor. Seminars in Perinatology, 2006, 30(1): 34-43.
[5] 张巍, 童笑梅, 王丹华. 早产儿医学[M]. 北京: 人民卫生出版社, 2008: 53-58.
[6] 张国友, 朱科明, 邓小明. ARDS发病机制和治疗研究新进展[J].《国外医学》麻醉学与复苏分册, 2005, 26(2): 102-103.
[7] M. Hogan, M. Kuliszewski, W. Lee, et al. Regulation of phospatidycholine synthesis inmaturing type II cells: Increased mRNA stability of CTP: Phosphocholine cytidylyltransferase. Bioche- mical Journal, 1996, 314: 799-803.
[8] E. P. Davis, E. L. Townsend, M. R. Gunnar, et al. Effects of prenatal betamethasone exposure on regulation of stress physiology in healthy premature infants. Psychoneuroendocrinology, 2004, 29(8): 1028-1036.
[9] G. Gragic, Z. Fatusic and G. Bogdanovic. Stimulation of fetal maturation with dexamethasone in unexpected premature labor. Medical Archives, 2003, 57(5-6): 291-294.
[10] J. B. Laoag-Femandez, A. M. Femandez and T. Maruo. Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome. Journal of Obstetrics and Gynaecology Research, 2000, 26(4): 307-312.
[11] C. Dani, P. V. Grella, L. Lazzarin, et al.•Antenatal ambroxol treatment does not prevent the respiratory distress syndrome in premature infants. European Journal of Pediatrics, 1997, 156(5): 392-393.
[12] S. Ruocco, A. Lallemand, J. M. Tounier, et al. Expression and localization of epidermal growth factor, transfering growth factor-a, and localization of their common receptor in fetal human lung development. Pediatric Research, 1996, 39: 448.
[13] A. Andreas, J. Frans, C. Waltherb, A. J. Waring, et al. Synthetic surfactant based on analogues of SP-B and SP-C is superior to single-peptide surfactants in ventilated premature rabbits. Neonatology, 2010, 98(1): 91-99.
[14] P. Timothy, M. D. Stevens. Surfactant replacement therapy. Chest, 2007, 131(5): 1577-1582.
[15] D. G. Sweet, V. Carnielli, G. Greisen, et al. The prevention and treatment of neonatal distress syndrome in European. Chinese Journal of Contemporary Pediatrics, 2011, 49(1): 27-33.
[16] M. Mario, R. Beatrice. Ambroxol in the 21st century: Pharmacological and clinical update. Expert Opinion on Drug Metabolism & Toxicology, 2008, 4(8): 1119-1129.
[17] K. M. Beeh, J. Beier, A. Esperester and D. Paul. Antiinflammatory properties of ambroxol. European Journal of Medical Research, 2008, 13(12): 557-562.
[18] 邝土光, 张洪玉, 庞宝森等. 氨溴索弱化机体氧化/抗氧化失衡的实验与临床观察[J]. 中华医学杂志, 2001, 81(8): 506- 507.
[19] L. Andreas, R. Jennifer and N. Carla. Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. European Journal of Pharmacology, 2010, 630(1-3): 19-28.
[20] C. J. Morley, G. Peter, et al. Nasal CPAP or intubation at birth for very preterm infants. New England Journal of Medicine, 2008, 358(7): 700-708.
[21] A. R. Mario, M. L. Juan and X. R. Maria. Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: A randomized, controlled trial. Pediatrics, 2009, 123(1): 137-142.
[22] E. C. Shannon, L. Katherine and C. P. Fedor. Effects of imposed resistance on tidal volume with 5 neonatal nasal continuous po- sitive airway pressure systems. Respiratory Care, 2010, 55(5): 544-548.
[23] G.-J. Chen, L. Guo and Z.-Y. Xiao. A comparative study on early applying of B-NCPAP 8 cm H2O with PS plus B-NCPAP 5 cm H2O in neonatal respiratory distress syndrome. Chinese Journal of Evidence Based Pediatrics, 2009, l4(5): 295-300.
[24] Y.-P. Cui, X.-M. Tong, H.-M. Ye, et al. A meta analysis of nasal intermittent positive pressure ventilation in treatment of respiratory distress syndrome in premature infants. Chinese Journal of Pediatrics, 2009, 47(7): 532-535.
[25] H. K. Vonder, M. A. Kandler, L. Fink, et al. High-frequency oscillation ventilation suppresses inflammatory response in lung tissue and microdissected alveolar macrophages in surfactant depleted piglets. Pediatrics Research, 2003, 55(2): 1-8.
[26] Z.-J. Liu, S.-T. Li, H. Hao, et al. The safety analysis of high- frequency oscillatory ventilation for neonatal respiratory distress syndrome. Journal of Clinical Pediatrics, 2008, 26(3): 191-194.
[27] J. N. Ben, K. Mnif, A. Khaldi, et al. High-frequency oscillatory ventilation in term and near-term infants with acute respiratory failure: Early rescue use. American Journal of Perinatology, 2006, 23(7): 403-411.
[28] T. T. Colaizy, U. M. Younis and E. F. Bell. Nasal high-frequency ventilation for premature infants. Acta Paediatrica, 2008, 97(11): 1518-1522.
[29] F. Cools, L. M. Askie and M. Offringa. Elec-tive high-frequency oscillatory ventilation in preterm infants with respiratory distress syndrome: An individual patient data meta-analysis. BMC Pediatr, 2009, 16(9): 33.
[30] Q. Yang, B. Sun. Experimental research and clinical application of inhaled nitric oxide in premature neonates. Journal of Clinical Pediatric, 2009, 27(3): 210-213.
[31] S. Hosono, T. Ohno and H. Kimoto. Developmental outcomes in persistent pulmonary hypertension treated with nitric oxide therapy. Pediatrics Interantional, 2009, 51(1): 79-83.
[32] Y. J. Lin, N. E. Markham, V. Balasubramaniam, et al. Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatric Research, 2005, 58(1): 22-29.
[33] K. J. Barrington, N. Finer. Inhaled nitric oxide for respiratory failure in preterm infants. Pediatrics, 2011, 128(1): 255-256.
[34] J. C. Mercier, H. Hummler, X. Durrmeyer, M. Sanchez-Luna, et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): A randomised controlled trial. Lancet, 2010, 376(9738): 346-354.
[35] H. Chang, F. C. Kuo, Y. S. Lai, et al. Inhibition of inflammatory responses by FC-77, a Perfluorochemicalin lipopolysaccharide- treated RAW264.7 macrophages. Intensive Care Medicine, 2005, 31(7): 977-984.
[36] Y.-B. Zhu, Q. Wang, Y.-L. Liu, et al. Effect of partial liquid ventilation on oleic ac-id-induced inflammatory responses in piglets. Chinese Medical Journal, 2010, 123(15): 2088-2093.
[37] M. R. Wolfson, R. B. Hirschl, J. C. Jackson, et al. Multicenter comparative study of conventional mechanical gas ventilation to tidal liquid ventilation in oleic acid injured sheep. ASAIO Journal, 2008, 54(3): 256-269.
[38] S. Liu, L. B. Sun, Y. H. Mi, et al. Extracorporeal membrane oxygenation (ARDS) in patients of different causes. Journal of Cardiovascular and Pulmonary Diseases, 2011, 30(1): 8-12.
[39] J. R. Pohlmann, D. O. Brant, M. A. Daul, et al. Total liquid ventilation provides superior respiratory support to con-ventional mechanical ventilation in a large animal model of severe respiratory failure. ASAIO Journal, 2011, 57(1): 1-8.
[40] C. Long. The opportunities and challenges of extracorporeal membrane oxygenation on Chinese cardiopulmonary bypass in this century. Chinese Journal of Extracorporeal Circulation, 2005, 3(2): 65.
[41] Y.-H. Chen, B.-D. Zhang, D.-K. Liang, et al. Treatment of extracorporeal membrane oxygenation on acute lung injury. China Journal of Modern Medicine, 2011, 21(19): 2215-2218.
[42] T. Schaible, D. Hermle, F. Loersch, et al. A 20-year experience on neonatal extracorporeal membrane oxygenation in a referral center. Intensive Care Medicine, 2010, 36(7): 1229-1234.
[43] E. Khoshbin, D. Machin, H. Killer, et al. A potential propensity for failure secondary to clot embolism in neonatal ECMO. Perfusion, 2005, 20(3): 177-181.